Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides.
about
Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancerHDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs?Evaluation of histone deacetylases as drug targets in Huntington's disease models. Study of HDACs in brain tissues from R6/2 and CAG140 knock-in HD mouse models and human patients and in a neuronal HD cell modelExploration of Novel Inhibitors for Class I Histone Deacetylase Isoforms by QSAR Modeling and Molecular Dynamics Simulation AssaysInsecticidal activities of histone deacetylase inhibitors against a dipteran parasite of sheep, Lucilia cuprinaCarbamate prodrug concept for hydroxamate HDAC inhibitors.Genetic deletion of the Histone Deacetylase 6 exacerbates selected behavioral deficits in the R6/1 mouse model for Huntington's disease.Specific activity of class II histone deacetylases in human breast cancer cellsProtein kinase D1 mediates class IIa histone deacetylase phosphorylation and nuclear extrusion in intestinal epithelial cells: role in mitogenic signalingA novel HDAC inhibitor with a hydroxy-pyrimidine scaffoldSynthesis and biological evaluation of largazole analogues with modified surface recognition cap groupsClass I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancerDeacetylation of the DNA-binding domain regulates p53-mediated apoptosisClass II HDAC inhibition hampers hepatic stellate cell activation by induction of microRNA-29Nε-lysine acetylation determines dissociation from GAP junctions and lateralization of connexin 43 in normal and dystrophic heart.HDAC inhibitors repress BARD1 isoform expression in acute myeloid leukemia cells via activation of miR-19a and/or b.Histone deacetylase regulation of immune gene expression in tumor cells.Inhibition of histone deacetylase 4 increases cytotoxicity of docetaxel in gastric cancer cells.Promiscuous actions of small molecule inhibitors of the protein kinase D-class IIa HDAC axis in striated muscleOn the inhibition of histone deacetylase 8Class IIa histone deacetylases affect neuronal remodeling and functional outcome after strokeHistone deacetylase inhibitors: clinical implications for hematological malignancies.Inhibition of HDAC9 increases T regulatory cell function and prevents colitis in mice.RhoB upregulation leads to either apoptosis or cytostasis through differential target selection.Discovery of histone deacetylase 8 selective inhibitors.Amino acid starvation induces reactivation of silenced transgenes and latent HIV-1 provirus via down-regulation of histone deacetylase 4 (HDAC4)PGE2 induces interleukin-8 derepression in human astrocytoma through coordinated DNA demethylation and histone hyperacetylation.Discovery and development of SAHA as an anticancer agent.Myocyte enhancer factor 2 and class II histone deacetylases control a gender-specific pathway of cardioprotection mediated by the estrogen receptor.A nitric oxide-dependent cross-talk between class I and III histone deacetylases accelerates skin repairThe therapeutic uses of chromatin-modifying agents.Histone deacetylase inhibitors and hemoglobin F induction in beta-thalassemiaIsoform-selective histone deacetylase inhibitorsDetrimental effect of class-selective histone deacetylase inhibitors during tissue regeneration following hindlimb ischemia.Computational studies on the histone deacetylases and the design of selective histone deacetylase inhibitors.Multiple roles of HDAC inhibition in neurodegenerative conditions.Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells.Histone deacetylase inhibitors (HDACIs). Structure--activity relationships: history and new QSAR perspectives.Small-molecule chromatin-modifying agents: therapeutic applications.Therapeutic potential of isoform selective HDAC inhibitors for the treatment of schizophrenia.
P2860
Q26777453-2174EE6C-DBE1-4359-AE41-42F87FD863EBQ27015801-10604E90-12BF-484B-9F23-CF0CA83F9CC0Q28475537-756FE8D1-901E-4D62-BEB9-FDC71C4B628BQ28550025-56CF4823-2435-4486-85E7-F45CC608DFE5Q28818731-5ED3F9FD-B744-4FA2-B9AA-40869794AF22Q30318440-9740AD72-8306-4C82-954F-8C8372445B25Q30401432-B494B36F-D711-49A0-A59E-7875B379C7C0Q33606021-F840CF36-3B59-46D6-8890-1D424655990EQ33626512-38DC5B35-E6A8-41B1-9C9F-0FD72A260992Q33940304-BC016C07-8D3C-4D40-AB4B-2B36ED5243CBQ34302247-93CAEA06-EC5A-4110-9637-C903F93EE77EQ34318452-426DE9ED-C6D1-4E16-9295-44E904F0E9B0Q34575823-2A5613CF-11F1-447C-A43E-A1AEF211F7FBQ34576966-1D211214-0C2A-4F72-B84E-E89D829EDB67Q34582749-E3B1645D-5AE8-4D1A-8C3F-1F076962AE7BQ35070712-1C050477-38FB-4D22-A705-6E039147BD81Q35092304-D653BA81-4C78-4749-A066-62C65427C41EQ35219054-CBC916CA-7D25-463F-B1A9-E362D5783767Q35541203-D2037BE2-98E8-44CF-B92C-9F020904BEF1Q35633424-743DA5F6-197E-4645-9494-3D92584DBB3BQ35996642-430D79E0-5E19-46D0-AB61-FC4C0B9AC135Q36001847-C3777630-19BE-4F12-B5FE-F5FC3E991A27Q36014379-6FF12554-F638-416D-88FB-2A2B9648450CQ36027160-E8FC5213-A1F0-4973-887C-49A18A29BA58Q36111962-D4C96CE6-4A4C-4B9A-A97F-02FA9BA81C1CQ36187278-870A7A74-CE91-4E63-AD4E-D53F98107B34Q36402780-4DA1EEAE-4135-4FFB-BD3B-79B43E15EB0CQ36745383-3EF5933B-4FC7-4F12-8015-75C30512F0AAQ36758584-B704A933-A11F-42D8-BA30-D9079EE2BF12Q36779668-62B8393C-C9F8-449B-B377-218D884D4230Q36822457-5E8F5877-2BA3-4F58-BEF8-B093F07DF816Q36968042-AF433BED-8746-4C1F-9F0C-10C7E11ABB42Q36995048-6F49D7B4-96D5-40B6-8253-F552AF20B3E8Q37095364-6C51A87A-6763-4774-B9B5-FF493C00C00BQ37397325-AB2FD530-81E0-460E-A97E-36B034DF8411Q37407855-3739578D-BAF9-437F-BD81-96ED0095360FQ37621254-E4728C3C-7664-4FC2-B9F3-6BE285A5A67BQ37693855-4555EA26-2703-48BA-AFA0-2A6103845A66Q37961728-53706FF4-D394-4AB3-9EE6-CDD9F57A659CQ38136307-A85C5F50-0D1E-4142-A4BD-38EE51D9ADB3
P2860
Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Class II (IIa)-selective histo ...... openyl)pyrrolyl hydroxyamides.
@en
type
label
Class II (IIa)-selective histo ...... openyl)pyrrolyl hydroxyamides.
@en
prefLabel
Class II (IIa)-selective histo ...... openyl)pyrrolyl hydroxyamides.
@en
P2093
P50
P356
P1476
Class II (IIa)-selective histo ...... openyl)pyrrolyl hydroxyamides.
@en
P2093
Annamaria Scognamiglio
Gerald Brosch
Peter Loidl
Riccardo Pezzi
Silvia Simeoni
Silvio Massa
P304
P356
10.1021/JM049002A
P407
P577
2005-05-01T00:00:00Z